Overview
Systemic lupus erythematosus (SLE) is a chronic autoimmune condition in which the immune system attacks healthy tissue throughout the body. It can affect almost any organ, including the skin, joints, kidneys, heart, brain, and blood. It follows a relapsing-remitting course and ranges from mild to life-threatening. It is far more common in women, especially during the reproductive years.
How common is it?
Lupus affects more women than men, but can occur in anyone. It is more common in women with African, Caribbean or Asian backgrounds; severity and organ involvement vary between individuals.
Causes and risk factors
SLE results from loss of immune tolerance, leading to autoantibody production against nuclear antigens. Both genetic and environmental triggers contribute.
Common risk factors
- Genetic susceptibility (HLA-DR2, HLA-DR3; numerous other susceptibility genes)
- Sex-related and hormonal factors contribute to susceptibility; lupus is more common in women.
- Ultraviolet light exposure (triggers and worsens flares)
- Infections (Epstein-Barr virus association)
- Medications: hydralazine, procainamide, isoniazid (drug-induced lupus)
- Hormonal contraception (may exacerbate in susceptible individuals)
- Some ethnic groups have higher rates of SLE and may experience more severe disease; individual outcomes vary.
Symptoms
- A butterfly-shaped rash across the cheeks and nose can occur, but is not present in everyone.
- Photosensitivity: rash or flare after sun exposure
- Joint pain and swelling (arthritis)
- Fatigue
- Oral ulcers
- Hair loss (alopecia)
- Serositis: pleurisy or pericarditis
- Kidney involvement (lupus nephritis): protein in urine, hypertension, oedema
- Neuropsychiatric manifestations: headache, seizures, psychosis
- Raynaud's phenomenon
- Blood count abnormalities: anaemia, low white cells, low platelets
When to see a doctor
Seek assessment for an unexplained rash, swollen joints or symptoms affecting several body systems, regardless of sex or age. In known lupus, new swelling or reduced urine needs prompt advice. Chest pain, severe breathlessness, seizures or sudden neurological symptoms need emergency assessment.
Diagnosis
ANA (antinuclear antibody) positive in 95 to 99% — highly sensitive but not specific. Anti-dsDNA and anti-Smith antibodies are more specific. Complement levels (C3, C4) low in active disease. Full blood count, urine protein:creatinine ratio. Classification uses EULAR/ACR 2019 criteria.
Treatments
Hydroxychloroquine
Hydroxychloroquine is commonly recommended unless unsuitable and can reduce flares. Eye monitoring is required according to duration of use and risk factors; follow the specialist screening plan and report visual changes.
NSAIDs and corticosteroids
Anti-inflammatory medicines may help some joint pain, but can be unsuitable with kidney disease, ulcers or pregnancy. Steroids may control flares and should be minimised by the prescriber; they can raise glucose. Do not change or stop them yourself.
Immunosuppressants
Immunosuppressants are selected for the organs affected. Some, including mycophenolate and methotrexate, can harm a pregnancy. Discuss contraception and pregnancy plans with your specialist before conception; do not stop treatment yourself.
Belimumab
A biologic that blocks B-cell survival factor (BLyS/BAFF). Licensed for active seropositive SLE. Reduces flare rate and steroid requirements.
Anifrolumab
Anifrolumab targets type I interferon signalling and is an option in some settings for selected adults with active SLE despite standard treatment. Access and funding vary; it is not a routine option for everyone.
Self-care and lifestyle
- Use high-factor (SPF 50) broad-spectrum sunscreen every day
- Wear sun-protective clothing and avoid peak sun hours
- Do not smoke (smoking worsens SLE and reduces hydroxychloroquine efficacy)
- Avoid oestrogen-containing contraception if antiphospholipid antibodies are present
Prevention
SLE cannot be prevented. Avoiding known triggers (sun exposure, smoking, certain drugs) may reduce flare frequency.
Sources for targeted updates
Updated: 24 October 2026. Targeted corrections to risk factors, urgent-care guidance, treatment, key facts, frequency, symptoms. This update covers the named sections; a full review of the remaining guide is pending.